Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Accounts Payables (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Accounts Payables for 6 consecutive years, with $7.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Accounts Payables fell 45.34% to $7.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.7 million, a 45.34% decrease, with the full-year FY2025 number at $7.7 million, down 45.34% from a year prior.
  • Accounts Payables was $7.7 million for Q4 2025 at Relay Therapeutics, up from $2.8 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $14.8 million in Q2 2023 to a low of $2.8 million in Q3 2025.
  • A 5-year average of $8.7 million and a median of $8.2 million in 2021 define the central range for Accounts Payables.
  • Peak YoY movement for Accounts Payables: surged 243.99% in 2023, then plummeted 59.92% in 2025.
  • Relay Therapeutics' Accounts Payables stood at $8.3 million in 2021, then grew by 27.82% to $10.6 million in 2022, then fell by 12.92% to $9.2 million in 2023, then skyrocketed by 53.05% to $14.1 million in 2024, then tumbled by 45.34% to $7.7 million in 2025.
  • Per Business Quant, the three most recent readings for RLAY's Accounts Payables are $7.7 million (Q4 2025), $2.8 million (Q3 2025), and $5.2 million (Q2 2025).